Anzeige
Mehr »
Dienstag, 05.08.2025 - Börsentäglich über 12.000 News
Warum Guardian Metal die Pentagon-gestützte Antwort auf Chinas Dominanz ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FiercePharma

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
MoAbbVie flashes eye-opening results for Rinvoq in alopecia areata
MoIncyte's new CEO pledges 'fresh look' at business, outlines dealmaking strategy
MoLilly confirms plan to sell NJ plant amid larger US production ramp-up
SaRegulatory tracker: AstraZeneca's Imfinzi stomach cancer expansion bid snags FDA priority review
FrRegeneron says Novo plant problems caused another CRL and will delay 2 Eylea decisions
FrLenz's Vizz wins FDA approval to crack 'large, untapped' market for presbyopia
FrDespite ongoing decline, Moderna's Spikevax sales beat expectations in Q2
FrJ&J coins the term '3rd opinion,' debuts awareness campaign to empower lung cancer patients
FrMerz Aesthetics gives sales and marketing leadership a face-lift
FrAlnylam exceeds $50B market cap as Amvuttra heart disease launch wows Wall Street
DoWhite House threatens to 'deploy every tool in our arsenal' to implement most-favored-nation drug pricing
DoMerck will lay off 6,000, reducing workforce by 8% in cost-cutting purge
DoSanofi touts tariff resilience for rest of 2025 as CEO admits many unknowns persist
DoAstraZeneca's Alexion spotlights generalized myasthenia gravis for next entry in awareness-raising film series
DoHHS will demo drugmakers' 340B rebate model in limited pilot program
DoAbbVie's rumored $1B pursuit of Gilgamesh could fit into its growing neuroscience portfolio
DoBiogen raises sales outlook as Leqembi awaits FDA decision on new dosing option
DoBristol Myers touts commercial execution, reckons with recent clinical setbacks
DoEvotec offloads France biosimilars plant to Sandoz for $300M
DoModerna, working through operating cost and R&D cuts, to sideline 10% of global workforce by year-end
DoVinay Prasad's exit signals FDA's probable slip toward more permissive regulation of cell and gene therapy: analyst
DoLilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
MiJ&J, Legend crunch the multiple myeloma numbers in first Carvykti TV ad
MiCelltrion closes in on US plant purchase, dubbing drug substance facility 'fundamental' to tariff mitigation
MiFDA taps newly appointed George Tidmarsh as acting CBER leader after Prasad exit